Publication | Closed Access

Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

UrologyOncologyGenitourinary CancerImmune Checkpoint InhibitorFirst-line TreatmentPharmacotherapyCancer TreatmentMedicineMolecular Oncology